Spit et al. (63) showed that tumorigenic RNF43 mutations exhibited synergistic effects with TP53 mutations and were more resistant to treatment with Wnt inhibitors, which differed from RNF43 loss-of-function mutations, through the culture of CRC organoids. The gene discussed is TP53; the disease is colorectal carcinoma.